Teveten was launched in Germany for the treatment of hypertension. There
are several ways in which it has been prepared, the shortest of which is four steps;
beginning with displacement of 2-butyl-4-chloroimidazole-5-carboxaldehyde with
methyl 4-(bromomethyl)benzoate. Teveten is an angiotensin Ⅱ antagonist selective for
the AT, subtype receptor. It is a potent, highly selective, competitve antagonist with no
agonist activity. Duration of action is similar to Enalapril (greater than 12 hr) but
Teveten had a faster onset. While it is orally active, it rapidly dissociates from the
receptor. This is contrary to its prolonged duration of action, which presumably results
from slow removal from compartments within tissue, cells or matrix around the AT,
receptor. It is not bound by BSA.
